Imipraminoxide
Clinical data | |
---|---|
Trade names | Imiprex, Elepsin |
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Elimination half-life | Intravenous: 1.8 hours[2] |
Identifiers | |
| |
ECHA InfoCard | 100.027.188 |
Chemical and physical data | |
Formula | C19H24N2O |
Molar mass | 296.414 g·mol−1 |
Imipraminoxide (brand names Imiprex, Elepsin), or imipramine N-oxide, is a tricyclic antidepressant (TCA) that was introduced in Europe in the 1960s for the treatment of depression.[3][4][5][6]
Imipraminoxide is both an
Imipraminoxide's
Imipraminoxide has been said to be a prodrug of imipramine.[13]
See also
References
- ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
- ISBN 978-3-527-64565-7.
- ISBN 3-88763-075-0.
- ISBN 0-412-54090-8.
- PMID 13944543.
- PMID 5133241.
- ^ S2CID 37508967.
- ^ ISBN 978-0-444-53266-4.
- ^ PMID 4947298.
- ^ ISBN 0-7817-3481-9.
- ^ S2CID 13172168.
- ^ S2CID 5970487.
- ISBN 978-3-527-64632-6.